Work

ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer

Year: 2025

Type: article

Abstract: • This ESMO Clinical Practice Guideline Express Update addresses developments in the management of metastatic pancreatic cancer. • It has been issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX regimen). • Updated first- and second-line treatment recommendations are provided. • An updated management algorithm for metastatic pancreatic cancer is also included.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104528

Authors: T. Conroy, M. Ducreux

Institutions: Inserm, Institut de Cancérologie de Lorraine, Interdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes – Région Est, Université de Lorraine, Université Paris-Saclay, Institut Gustave Roussy

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Merck KGaA, Les Laboratories Pierre Fabre, BeiGene, Kasturba Medical College, Manipal, European Society for Medical Oncology, Servier, Ipsen, Daiichi Sankyo Europe

OpenAlex ID: W4409302508

FWCI: 13.23

Cites: 12

Cited by: 36

Related to: 10